GRPR and neoplasm: In summary, these peptide-based radiopharmaceuticals, which retain binding specificity to GRPR, demonstrated high yields, high stability, high tumor uptake, and rapid clearance of radioactivity from blood or physiologic non-GRPR-expressing organs in rodent models and humans.